Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 9, Issue 7, Pages 831-840Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590903005552
Keywords
cytokine-induced killer; donor lymphocyte infusion; graft versus host disease; graft versus tumor
Funding
- Associazione Italiana per la Ricerca sul Cancro
- Ricerca Sanitaria Finalizzata
- Regione Piemonte
- Associazione Donatrici Italiane Sangue Cordone Ombelicale Organizzazioni non lucrative di utilita sociale (ADISCO ONLUS)
Ask authors/readers for more resources
Donor lymphocyte infusion (DLI) is used to increase the graft versus tumor (GVT) effect after allogeneic hematopoietic cell transplant (HCT). The limited spectrum of activity and high risk of graft versus host disease (GVHD) remain major limitations of this approach. The finding of new cell populations for adoptive immunotherapy, with the ability to separate GVT from GVHD, would be useful. Here we review the main basic, preclinical and clinical research on cytokine-induced killer (CIK) cells, highlighting the aspects of their antitumor and alloreactive potentials that might favourably affect the balance between GVT and GVHD. CIK cells are ex vivo-expanded T lymphocytes sharing NK markers and endowed with a potent MHC-unrestricted antitumor activity against haematological and solid malignancies. Studies in preclinical animal models have demonstrated their low GVHD potential when infused across MHC-barriers, and recent clinical studies seem to confirm these findings in patients with hematological malignances relapsing after HCT. If consolidated with larger clinical trials, adoptive immunotherapy with CIK cells might represent an effective alternative to classic DLI, helping HCT to succesfully meet current challenges like the extension across major HLA-barriers and application to solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available